Market revenue in 2023 | USD 88.1 million |
Market revenue in 2030 | USD 213.1 million |
Growth rate | 13.5% (CAGR from 2023 to 2030) |
Largest segment | Iron sucrose |
Fastest growing segment | Ferric Carboxymaltose |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Iron Dextran, Iron Sucrose, Ferric Carboxymaltose |
Key market players worldwide | AbbVie Inc, Civitas Resources Inc Ordinary Shares, Daiichi Sankyo Co Ltd, Sanofi SA, CSL Ltd, COSMOS Pharmaceutical Corp, Zydus Lifesciences, Rockwell Medical Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intravenous iron drugs market will help companies and investors design strategic landscapes.
Iron sucrose was the largest segment with a revenue share of 52.44% in 2023. Horizon Databook has segmented the Canada intravenous iron drugs market based on iron dextran, iron sucrose, ferric carboxymaltose covering the revenue growth of each sub-segment from 2018 to 2030.
As per Canadian Organ Replacement Register Annual Statistics 2019, over 50,000 people in Canada are being treated for kidney failure. As per the same source, around 58% of people with end-stage kidney disease are treated with dialysis. IV iron drug is considered as an effective treatment module for patients with dialysis-associated CKD.
Data from Government of Canada reported that nearly 300,000 people in the country could have celiac disease, but many remain undiagnosed. Gluten-containing food, if consumed by people with undiagnosed celiac disease, impairs the ability to absorb many nutrients, including iron.
Therefore, rise in the number of undiagnosed celiac disease in the country drives the demand for IV iron drugs. Government of Canada also reported that around 669,600 Canadian people 40 years & older live with diagnosed heart failure. Heart failure also results in iron deficiency, thereby driving the need for treatment with iron drugs.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada intravenous iron drugs market , including forecasts for subscribers. This country databook contains high-level insights into Canada intravenous iron drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account